New concepts in HIV-1 vaccine development

Current Opinion in Immunology

Volumn 41, Issue , 2016, Pages 39-46

  Stephenson, Kathryn E ^a,b   D'Couto, Helen T ^a   Barouch, Dan H ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ENVELOPE PROTEIN; EPITOPE; GAG PROTEIN; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADENOVIRIDAE; ANTIBODY RESPONSE; AVIADENOVIRUS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLADISTICS; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MEMORY CELL; NONHUMAN; PASSIVE IMMUNIZATION; REVIEW; SEROTYPE; THAILAND; VACCINE PRODUCTION; VIRUS REPLICATION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; VIROLOGY;

AIDS VACCINES; HIV INFECTIONS; HIV-1; HUMANS;

EID: 84973177464     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2016.05.011     Document Type: Review

References (86)

1. Fox M.P., Rosen S. Retention of adult patients on antiretroviral therapy in low- and middle-income countries. JAIDS J Acquir Immune Defic Syndr 2015, 69:98-108.
2. Schaecher K.L. The importance of treatment adherence in HIV. Am J Manage Care 2013, 19. s231-7.
3. Obiako O.R., Muktar H.M. Challenges of HIV treatment in resource-poor countries: a review. Niger J Med 2010, 19:361-368.
4. AIDS by the numbers 2015 | UNAIDS. 2015.
5. Barouch D.H., Deeks S.G. Immunologic strategies for HIV-1 remission and eradication. Science 2014, 345:169-174.
6. Chun T.-W., Justement J.S., Murray D., Hallahan C.W., Maenza J., Collier A.C., Sheth P.M., Kaul R., Ostrowski M., Moir S., et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 2010, 24:2803-2808.
7. Chun T.-W., Moir S., Fauci A.S. HIV reservoirs as obstacles and opportunities for an HIV cure. Nat Immunol 2015, 16:584-589.
8. Sigal A., Kim J.T., Balazs A.B., Dekel E., Mayo A., Milo R., Baltimore D. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2011, 477:95-98.
9. Hemelaar J. The origin and diversity of the HIV-1 pandemic. Trends Mol Med 2012, 18:182-192.
10. Hemelaar J., Gouws E., Ghys P.D., Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006, 20. W13-23.
11. Ndung'u T., Weiss R.A. On HIV diversity. AIDS 2012, 26:1255-1260.
12. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., Evans D.T., Montefiori D.C., Karnasuta C., Sutthent R., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012, 366:1275-1286.
13. Yates N.L., Liao H.-X., Fong Y., deCamp A., Vandergrift N.A., Williams W.T., Alam S.M., Ferrari G., Yang Z., Seaton K.E., et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med 2014, 6. 228ra39.
14. Zolla-Pazner S., deCamp A., Gilbert P.B., Williams C., Yates N.L., Williams W.T., Howington R., Fong Y., Morris D.E., Soderberg K.A., et al. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLOS ONE 2014, 9:e87572.
15. Rolland M., Edlefsen P.T., Larsen B.B., Tovanabutra S., Sanders-Buell E., Hertz T., deCamp A.C., Carrico C., Menis S., Magaret C.A., et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012, 490:417-420.
16. Plotkin S.A., Gilbert P.B. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 2012, 54:1615-1617.
17. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M., Adams E., Benenson M., Gurunathan S., Tartaglia J., McNeil J.G., Francis D.P., Stablein D., Birx D.L., Chunsuttiwat S., Khamboonruang C., Thongcharoen P., Rob M-T.I. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220.
18. Baden L.R., Walsh S.R., Seaman M.S., Johnson J.A., Tucker R.P., Kleinjan J.A., Gothing J.A., Engelson B.A., Carey B.R., Oza A., et al. First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002). J Infect Dis 2014, 210:1052-1061.
19. Barouch D.H., Liu J., Peter L., Abbink P., Iampietro M.J., Cheung A., Alter G., Chung A., Dugast A.-S., Frahm N., et al. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J Infect Dis 2013, 207:248-256.
20. Nkolola J.P., Bricault C.A., Cheung A., Shields J., Perry J., Kovacs J.M., Giorgi E., van Winsen M., Apetri A., Brinkman-van der Linden E.C.M., et al. Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer. J Virol 2014, 88:9538-9552.
21. Caskey M., Klein F., Lorenzi J.C.C., Seaman M.S., West A.P., Buckley N., Kremer G., Nogueira L., Braunschweig M., Scheid J.F., et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 2015, 522:487-491.
22. Wu X., Yang Z.-Y., Li Y., Hogerkorp C.-M., Schief W.R., Seaman M.S., Zhou T., Schmidt S.D., Wu L., Xu L., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861.
23. Forthal D.N., Gilbert P.B., Landucci G., Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 2007, 178:6596-6603.
24. Gilbert P.B., Peterson M.L., Follmann D., Hudgens M.G., Francis D.P., Gurwith M., Heyward W.L., Jobes D.V., Popovic V., Self S.G., et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005, 191:666-677.
25. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., Para M.F. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005, 191:654-665.
26. Pitisuttithum P., Gilbert P., Gurwith M., Heyward W., Martin M., van Griensven F., Hu D., Tappero J.W., Choopanya K. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006, 194:1661-1671.
27. Emu B., Sinclair E., Hatano H., Ferre A., Shacklett B., Martin J.N., McCune J.M., Deeks S.G. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J Virol 2008, 82:5398-5407.
28. Cao Y., Qin L., Zhang L., Safrit J., Ho D.D. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995, 332:201-208.
29. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., Gilbert P.B., Lama J.R., Marmor M., Del Rio C., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372:1881-1893.
30. Duerr A., Huang Y., Buchbinder S., Coombs R.W., Sanchez J., del Rio C., Casapia M., Santiago S., Gilbert P., Corey L., et al. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis 2012, 206:258-266.
31. Gray G.E., Allen M., Moodie Z., Churchyard G., Bekker L.-G., Nchabeleng M., Mlisana K., Metch B., de Bruyn G., Latka M.H., et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 2011, 11:507-515.
32. Letvin N.L., Rao S.S., Montefiori D.C., Seaman M.S., Sun Y., Lim S.-Y., Yeh W.W., Asmal M., Gelman R.S., Shen L., et al. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci Transl Med 2011, 3. 81ra36.
33. Churchyard G.J., Morgan C., Adams E., Hural J., Graham B.S., Moodie Z., Grove D., Gray G., Bekker L.-G., McElrath M.J., et al. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS ONE 2011, 6:e21225.
34. Hammer S.M., Sobieszczyk M.E., Janes H., Karuna S.T., Mulligan M.J., Grove D., Koblin B.A., Buchbinder S.P., Keefer M.C., Tomaras G.D., et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 2013, 369:2083-2092.
35. Excler J.L., Plotkin S. The prime-boost concept applied to HIV preventive vaccines. AIDS 1997, 11(Suppl. A). S127-37.
36. Bonsignori M., Pollara J., Moody M.A., Alpert M.D., Chen X., Hwang K.-K., Gilbert P.B., Huang Y., Gurley T.C., Kozink D.M., et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 2012, 86:11521-11532.
37. Liao H.-X., Bonsignori M., Alam S.M., McLellan J.S., Tomaras G.D., Moody M.A., Kozink D.M., Hwang K.-K., Chen X., Tsao C.-Y., et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 2013, 38:176-186.
38. Gray G.E., Andersen-Nissen E., Grunenberg N., Huang Y., Roux S., Laher F., Innes C., Gu N., DiazGranados C., Phogat S., et al. HVTN 097 evaluation of the RV144 vaccine regimen in HIV uninfected South African adults. AIDS Res Hum Retroviruses 2014, 30:A33-A34.
39. O'Connell R.J., Kim J.H., Corey L., Michael N.L. Human immunodeficiency virus vaccine trials. Cold Spring Harb Perspect Med 2012, 2:007351.
40. McElrath M.J. Selection of potent immunological adjuvants for vaccine construction. Semin Cancer Biol 1995, 6:375-385.
41. Rhee E.G., Barouch D.H. Translational mini-review series on vaccines for HIV: harnessing innate immunity for HIV vaccine development. Clin Exp Immunol 2009, 157:174-180.
42. Vaccari M., Gordon S.N., Fourati S., Schifanella L., Cameron M., Keele B.F., Shen X., Tomaras G., Billings E., Rao M., et al. Adjuvant dependent mucosal V2 responses and RAS activation in vaccine induced protection from SIV mac251 acquisition. AIDS Res Hum Retroviruses 2014, 30:A64-A65.
43. HVTN Studies. HVTN Ongoing Protoc.
44. Barouch D.H., Alter G., Broge T., Linde C., Ackerman M.E., Brown E.P., Borducchi E.N., Smith K.M., Nkolola J.P., Liu J., et al. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science 2015, 349:320-324.
45. Barouch D.H., Stephenson K.E., Borducchi E.N., Smith K., Stanley K., McNally A.G., Liu J., Abbink P., Maxfield L.F., Seaman M.S., et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 2013, 155:531-539.
46. Ackerman M.E., Moldt B., Wyatt R.T., Dugast A.-S., McAndrew E., Tsoukas S., Jost S., Berger C.T., Sciaranghella G., Liu Q., et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods 2011, 366:8-19.
47. Barouch D.H., Picker L.J. Novel vaccine vectors for HIV-1. Nat Rev Microbiol 2014, 12:765-771.
48. Chung A.W., Kumar M.P., Arnold K.B., Yu W.H., Schoen M.K., Dunphy L.J., Suscovich T.J., Frahm N., Linde C., Mahan A.E., et al. Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology. Cell 2015, 163:988-998.
49. Fischer W., Perkins S., Theiler J., Bhattacharya T., Yusim K., Funkhouser R., Kuiken C., Haynes B., Letvin N.L., Walker B.D., et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 2007, 13:100-106.
50. Ndhlovu Z.M., Piechocka-Trocha A., Vine S., McMullen A., Koofhethile K.C., Goulder P.J.R., Ndung'u T., Barouch D.H., Walker B.D. Mosaic HIV-1 Gag antigens can be processed and presented to human HIV-specific CD8+ T cells. J Immunol 2011, 186:6914-6924.
51. Thurmond J., Yoon H., Kuiken C., Yusim K., Perkins S., Theiler J., Bhattacharya T., Korber B., Fischer W. Web-based design and evaluation of T-cell vaccine candidates. Bioinformatics 2008, 24:1639-1640.
52. Kothe D.L., Li Y., Decker J.M., Bibollet-Ruche F., Zammit K.P., Salazar M.G., Chen Y., Weng Z., Weaver E.A., Gao F., et al. Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology 2006, 352:438-449.
53. Barouch D.H., O'Brien K.L., Simmons N.L., King S.L., Abbink P., Maxfield L.F., Sun Y.-H., La Porte A., Riggs A.M., Lynch D.M., et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010, 16:319-323.
54. Stephenson K.E., SanMiguel A., Simmons N.L., Smith K., Lewis M.G., Szinger J.J., Korber B., Barouch D.H. Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys. J Virol 2012, 86:11434-11440.
55. Santra S., Muldoon M., Watson S., Buzby A., Balachandran H., Carlson K.R., Mach L., Kong W.-P., McKee K., Yang Z.-Y., et al. Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens. Virology 2012, 428:121-127.
56. Stamatatos L. HIV vaccine design: the neutralizing antibody conundrum. Curr Opin Immunol 2012, 24:316-323.
57. Hraber P., Korber B.T., Lapedes A.S., Bailer R.T., Seaman M.S., Gao H., Greene K.M., McCutchan F., Williamson C., Kim J.H., et al. Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies. J Virol 2014, 88:12623-12643.
58. Klein F., Mouquet H., Dosenovic P., Scheid J.F., Scharf L., Nussenzweig M.C. Antibodies in HIV-1 vaccine development and therapy. Science 2013, 341:1199-1204.
59. Stamatatos L., Morris L., Burton D.R., Mascola J.R. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. Nat Med 2009, 15:866-870.
60. Moore P.L., Gray E.S., Wibmer C.K., Bhiman J.N., Nonyane M., Sheward D.J., Hermanus T., Bajimaya S., Tumba N.L., Abrahams M.-R., et al. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med 2012, 18:1688-1692.
61. Klein J.S., Bjorkman P.J. Few and far between: how HIV may be evading antibody avidity. PLoS Pathog 2010, 6:e1000908.
62. Moldt B., Rakasz E.G., Schultz N., Chan-Hui P.-Y., Swiderek K., Weisgrau K.L., Piaskowski S.M., Bergman Z., Watkins D.I., Poignard P., et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A 2012, 109:18921-18925.
63. Mascola J.R., Lewis M.G., Stiegler G., Harris D., VanCott T.C., Hayes D., Louder M.K., Brown C.R., Sapan C.V., Frankel S.S., et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999, 73:4009-4018.
64. Parren P.W.H.I., Marx P.A., Hessell A.J., Luckay A., Harouse J., Cheng-Mayer C., Moore J.P., Burton D.R. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001, 75:8340-8347.
65. Hessell A.J., Rakasz E.G., Tehrani D.M., Huber M., Weisgrau K.L., Landucci G., Forthal D.N., Koff W.C., Poignard P., Watkins D.I., et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 2010, 84:1302-1313.
66. Hessell A.J., Rakasz E.G., Poignard P., Hangartner L., Landucci G., Forthal D.N., Koff W.C., Watkins D.I., Burton D.R. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009, 5:e1000433.
67. Pegu A., Yang Z., Boyington J.C., Wu L., Ko S.-Y., Schmidt S.D., McKee K., Kong W.-P., Shi W., Chen X., et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med 2014, 6. 243ra88.
68. Mann J.K., Ndung'u T. HIV-1 vaccine immunogen design strategies. Virol J 2015, 12:3.
69. Sanders R.W., Derking R., Cupo A., Julien J.-P., Yasmeen A., de Val N., Kim H.J., Blattner C., de la Peña A.T., Korzun J., et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog 2013, 9:e1003618.
70. Sanders R.W., Schiffner L., Master A., Kajumo F., Guo Y., Dragic T., Moore J.P., Binley J.M. Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits. J Virol 2000, 74:5091-5100.
71. Georgiev I.S., Joyce M.G., Yang Y., Sastry M., Zhang B., Baxa U., Chen R.E., Druz A., Lees C.R., Narpala S., et al. Single-chain soluble BG505.SOSIP gp140 trimers as structural and antigenic mimics of mature closed HIV-1 Env. J Virol 2015, 89:5318-5329.
72. Haynes B.F., Kelsoe G., Harrison S.C., Kepler T.B. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 2012, 30:423-433.
73. Johnson P.R., Schnepp B.C., Zhang J., Connell M.J., Greene S.M., Yuste E., Desrosiers R.C., Clark K.R. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 2009, 15:901-906.
74. Balazs A.B., Chen J., Hong C.M., Rao D.S., Yang L., Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012, 481:81-84.
75. Gardner M.R., Kattenhorn L.M., Kondur H.R., von Schaewen M., Dorfman T., Chiang J.J., Haworth K.G., Decker J.M., Alpert M.D., Bailey C.C., et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 2015, 519:87-91.
76. Nakamura K.J., Cerini C., Sobrera E.R., Heath L., Sinkala M., Kankasa C., Thea D.M., Mullins J.I., Kuhn L., Aldrovandi G.M. Coverage of primary mother-to-child HIV transmission isolates by second-generation broadly neutralizing antibodies. AIDS 2013, 27:337-346.
77. Russell E.S., Ojeda S., Fouda G.G., Meshnick S.R., Montefiori D., Permar S.R., Swanstrom R. Short communication: HIV type 1 subtype C variants transmitted through the bottleneck of breastfeeding are sensitive to new generation broadly neutralizing antibodies directed against quaternary and CD4-binding site epitopes. AIDS Res Hum Retroviruses 2013, 29:511-515.
78. Ledgerwood J.E., Coates E.E., Yamshchikov G., Saunders J.G., Holman L., Enama M.E., DeZure A., Lynch R.M., Gordon I., Plummer S., et al. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol 2015, 182:289-301.
79. Lynch R.M., Boritz E., Coates E.E., DeZure A., Madden P., Costner P., Enama M.E., Plummer S., Holman L., Hendel C.S., et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med 2015, 7. 319ra206.
80. Hansen S.G., Ford J.C., Lewis M.S., Ventura A.B., Hughes C.M., Coyne-Johnson L., Whizin N., Oswald K., Shoemaker R., Swanson T., et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473:523-527.
81. Hansen S.G., Vieville C., Whizin N., Coyne-Johnson L., Siess D.C., Drummond D.D., Legasse A.W., Axthelm M.K., Oswald K., Trubey C.M., et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009, 15:293-299.
82. Hansen S.G., Piatak M., Ventura A.B., Hughes C.M., Gilbride R.M., Ford J.C., Oswald K., Shoemaker R., Li Y., Lewis M.S., et al. Immune clearance of highly pathogenic SIV infection. Nature 2013, 502:100-104.
83. Patterson L.J., Kuate S., Daltabuit-Test M., Li Q., Xiao P., McKinnon K., DiPasquale J., Cristillo A., Venzon D., Haase A., et al. Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route. Clin Vaccine Immunol 2012, 19:629-637.
84. Xiao P., Patterson L.J., Kuate S., Brocca-Cofano E., Thomas M.A., Venzon D., Zhao J., DiPasquale J., Fenizia C., Lee E.M., et al. Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) ch. J Virol 2012, 86:4644-4657.
85. Maxfield L.F., Abbink P., Stephenson K.E., Borducchi E.N., Ng'ang'a D., Kirilova M.M., Paulino N., Boyd M., Shabram P., Ruan Q., et al. Attenuation of replication-competent adenovirus serotype 26 vaccines by vectorization. Clin Vaccine Immunol 2015, 22:1166-1175.
86. Rose N.F., Marx P.A., Luckay A., Nixon D.F., Moretto W.J., Donahoe S.M., Montefiori D., Roberts A., Buonocore L., Rose J.K. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001, 106:539-549.